{
  "docId": "019dd923-5ca1-7489-b639-45501f4b359b",
  "docSlug": "158df8627a0b9aca",
  "documentTitle": "Opioid Conflicts Majority Staff Report",
  "authorId": "McKinsey",
  "authorName": "U.S. House Committee on Oversight and Reform",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "portrait",
  "aspectRatio": 0.773,
  "pageNumber": 4,
  "pageCount": 53,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "appendix_disclosure",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "This slide appears to be part of a larger report or legal disclosure document, indicated by the page number '4' at the bottom.",
  "elementsJson": [
    "bullet_list"
  ],
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b639-45501f4b359b/4",
  "deckHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b#slide-4",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "McKinsey utilized its federal government contracts, connections, and influence to solicit private sector business.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-cdec-74db-b499-f5f9da3e7d04",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.23,
        "y": 0.62
      },
      "kind": "list",
      "text": "In 2016, a McKinsey partner encouraged other consultants to share information with Purdue about ongoing drug safety work McKinsey was doing for FDA, saying they should 'talk about our work w FDA.'",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30ca8201-22c4-4093-880c-e24a78112f82",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.71,
        "x": 0.17,
        "y": 0.29
      },
      "kind": "list",
      "text": "McKinsey utilized its federal government contracts, connections, and influence to solicit private sector business: Documents show McKinsey consultants sought to leverage their government contacts and experience to solicit private sector business.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b69eea2-111c-418b-8f60-8b1aca75c16f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.71,
        "x": 0.17,
        "y": 0.71
      },
      "kind": "list",
      "text": "McKinsey submitted opioid advice to the Trump Administration, including information that went to the HHS Secretary and FDA Commissioner: Documents show that McKinsey consultants with Purdue ties attempted to influence public health officials.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c77ffb9-abd3-4722-bff4-66b4a73b1f01",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.23,
        "y": 0.375
      },
      "kind": "list",
      "text": "In 2009, in a bid to lead a working group of opioid manufacturers, McKinsey highlighted that due to its direct work for regulators, the company had 'developed insights into the perspectives of the regulators themselves.'",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7250ecb3-ac5f-47b0-a928-12808a118621",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.65,
        "x": 0.23,
        "y": 0.46
      },
      "kind": "list",
      "text": "In 2014, a McKinsey partner wrote to Purdue's CEO that McKinsey brought an 'unequaled capability based on who we know and what we know,' highlighting the firm's work for 'State and Federal Regulators.'",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "752dc680-0b05-4583-b08f-3e465b34d026",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.23,
        "y": 0.115
      },
      "kind": "list",
      "text": "One senior McKinsey consultant worked on three FDA projects from 2014 to 2018 to assess the safety of dangerous drugs through the FDA Sentinel Initiative while simultaneously advising Purdue.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da409946-deda-4f08-b05a-0e29328edb1c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.65,
        "x": 0.23,
        "y": 0.185
      },
      "kind": "list",
      "text": "In 2017, a McKinsey partner began work on a $2.7 million contract to help modernize FDA's Office of New Drugs—at the same time the McKinsey consultant was advising Purdue on maximizing the market potential of a new opioid.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dbd44677-e829-4c85-9e5a-fdea49a5409d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.65,
        "x": 0.23,
        "y": 0.815
      },
      "kind": "list",
      "text": "In 2018, McKinsey consultants drafted a 'transition memo' to incoming HHS Secretary Alex Azar. The memo contained input from McKinsey consultants who did work for Purdue, including one who recommended strategies to 'Turbocharge Purdue's Sales Engine.'",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f23c7c26-084a-4288-95f2-d1270cb84400",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.02,
        "x": 0.49,
        "y": 0.935
      },
      "kind": "paragraph",
      "text": "4",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "720418b5-7151-4249-b0ad-a2d009410792",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "McKinsey brought an “unequaled capability based on who we know and what we know,” highlighting the firm’s work for “State and Federal Regulators,” including “FDA, who we have supported for over five years.”",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd951-cdec-74db-b499-fb0182696fda",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 1,
      "beatId": "879d5693-fa0d-471e-8bc6-dddb3a68ee78",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem & Complication",
      "beatSlug": "consultants-gambit-problem-complication",
      "evidence": "The document introduces the problem of McKinsey's conflicts of interest and complicates it through examples of overlapping work.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 53,
      "from": 1,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "ee9686db-f8b5-4bc9-bf6e-2d29966ee033",
      "evidence": "The document implies the cost of inaction through its presentation of McKinsey's conflicts of interest and their potential impact on the opioid epidemic.",
      "position": 0,
      "objective": "What is the cost of inaction in addressing McKinsey's conflicts of interest?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}